DHL has broken ground on a new cold chain hub at Singapore’s Changi Airport, marking a significant expansion of its pharmaceutical logistics capabilities in Asia.
The new facility underlines growing demand for temperature-controlled supply chains as pharmaceutical companies increasingly rely on cold storage to protect sensitive drug products during transit.
Singapore’s Changi Airport has long been regarded as one of the world’s premier air cargo hubs, making it a strategic location for pharmaceutical cold chain infrastructure serving Asia-Pacific markets.
The investment reflects a broader push by logistics providers to position themselves closer to key pharmaceutical manufacturing and distribution corridors across Southeast Asia.
Beyond logistics, the pharmaceutical industry’s commercial model is also undergoing significant change, according to a new report that describes the shift as a fundamental reset.
The report suggests that how pharmaceutical companies bring products to market is being rethought at its core, with traditional go-to-market strategies no longer fit for purpose in a rapidly evolving landscape.
Pressure from payers, shifting prescriber behaviours, and the growing complexity of speciality and rare disease portfolios are among the forces driving pharmaceutical companies to reconsider their commercial approaches.
Companies are being pushed to develop more targeted and efficient market access strategies as the cost of launching new drugs continues to rise alongside increasing regulatory and reimbursement scrutiny.
Adding to the week’s pharmaceutical developments, the US Food and Drug Administration has granted accelerated approval to sevabertinib, providing patients with a new treatment option.
Accelerated approval from the FDA allows promising drugs to reach patients sooner based on surrogate or intermediate clinical endpoints that are reasonably likely to predict clinical benefit.
The approval of sevabertinib represents another milestone for the agency’s accelerated pathway, which has become an increasingly important mechanism for bringing novel therapies to market.
Taken together, DHL’s Singapore investment, the reset of pharma’s commercial model, and the FDA’s approval of sevabertinib paint a picture of an industry navigating considerable transformation on multiple fronts simultaneously.